NCT05387980Active, not recruiting
A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.
CIBINQO® TABLETS SPECIAL INVESTIGATION
Source: ClinicalTrials.gov · Last updated 19 Mar 2026
Brief summary (registry, in English)
The purpose of this study is to learn about the safety and effectiveness (how well the study treatment works) of the study medicine (CIBINQO) for the potential treatment of atopic dermatitis in people under Japanese medical practice.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1128 (actual)
- First submitted
- 9 May 2022
- Start date
- 19 Apr 2022
- Primary completion date
- 1 Nov 2028
- Lead sponsor
- Pfizer
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT05387980
What you commit to
- Study type: Observational
- Participants enrolled: 1128
- From 19 Apr 2022 to the primary completion date, 1 Nov 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 1\. Participants previously enrolled in this Study at the same site.
Who the study is looking for
- Participants receiving this Product for treatment of AD.
- Participants start receiving this Product (commercial product) for the first time and no earlier than the contract date of this Study, or Participants who continues to receive this drug after hospital transfer can be registered retrospectively.
Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Local Country Office Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.